catalym
Posted by catalym
October 12, 2023
October 12, 2023

Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment

Markus Haake, Beatrice Haack, Tina Schäfer, Patrick N. Harter, Greta Mattavelli, Patrick...

Read More
catalym
Posted by catalym
July 20, 2023
July 20, 2023

CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance

CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor...

Read More
catalym
Posted by catalym
June 5, 2023
June 5, 2023

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody...

Read More
catalym
Posted by catalym
May 25, 2023
May 25, 2023

CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting

CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab...

Read More
catalym
Posted by catalym
December 14, 2022
catalym
Posted by catalym
November 22, 2022
catalym
Posted by catalym
September 26, 2022
September 26, 2022

CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the US

CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced...

Read More
catalym
Posted by catalym
September 10, 2022
September 10, 2022

CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination

CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for...

Read More
catalym
Posted by catalym
September 5, 2022
catalym
Posted by catalym
March 1, 2022
March 1, 2022

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase...

Read More
WordPress Cookie Notice by Real Cookie Banner